Specifically, whether the GR affects the expression of immune checkpoint inhibitors in NSCLC should be evaluated, since there is already evidence that GR signaling regulates PD-L1 expression and, thus, promotes immune evasion and immunotherapy resistance in other cancers [37,38,39]. This evidence concerns the gene NR3C1 and cancer.